Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Borken – page 54

1 431 clinical trials in Borken, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Borken at a glance
1 431
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 431 trials in Borken

Open in trial search

Embolism

Not yet recruiting

A study to evaluate the effectiveness of REGN7508 for preventing blood clots in adults with solid tumors undergoing cancer treatment.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 S228P Monoclonal Antibody Against Factor Xi And Activated Factor Xi
  • Sponsor:Regeneron Pharmaceuticals Inc.

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zampilimab
  • Sponsor:Chiesi Farmaceutici S.p.A.

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab
  • Sponsor:Pfizer Inc.

Endocrine ophthalmopathy

Not yet recruiting

A study testing teprotumumab compared to placebo in adult patients with moderate-to-severe active thyroid eye disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Pharyngitis

Not yet recruiting

Study of benzydamine hydrochloride and dichlorobenzyl alcohol lozenges for treating acute pharyngitis symptoms

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:2,4 dichlorobenzyl alcohol
  • Sponsor:MEDICE Arzneimittel Puetter GmbH & Co. KG

Prostate cancer

Not yet recruiting

Study of PSMA PET imaging versus standard imaging to guide radiation therapy in patients with intermediate or high-risk prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Universitaetsklinikum Essen AöR

Dermatitis atopic

Not yet recruiting

Study to evaluate ATI-045 injection compared to placebo in adults with moderate to severe atopic dermatitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST THYMIC STROMAL LYMPHOPOIETIN
  • Sponsor:Aclaris Therapeutics Inc.

Type 2 diabetes mellitus

Not yet recruiting

Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Insulin degludec
  • Sponsor:Novo Nordisk A/S

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Borken

What the registry says about research in the country

01 Neuropathic Pain Research

Investigating innovative treatments for patients with diabetic polyneuropathy, focusing on new therapeutic approaches for chronic pain management.

  • Diabetic Neuropathy
  • Pain Management
  • Treatment Efficacy

Clinical evaluations of add-on treatments aim to improve quality of life for patients with chronic neuropathic conditions.

02 Trauma-Related Neuropathy

Studies examining treatment options for post-operative and traumatic peripheral neuropathy, with emphasis on chronic pain relief strategies.

  • Post-Surgical Pain
  • Trauma-Induced Neuropathy
  • Pain Relief Solutions

Research focused on developing effective therapeutic interventions for trauma-related chronic pain conditions.

03 Central Neuropathy Studies

Comprehensive research into central neuropathy of various origins, evaluating novel treatment approaches for chronic pain management.

  • Central Nervous System
  • Pain Treatment
  • Therapeutic Efficacy

Advanced clinical trials exploring innovative solutions for central nervous system-related pain conditions.

04 Chronic Back Pain Treatment

Investigation of new therapeutic approaches for managing chronic back pain, focusing on treatment tolerability and effectiveness.

  • Back Pain Management
  • Pain Relief
  • Treatment Outcomes

Studies aimed at improving treatment options for patients suffering from persistent back pain conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.